(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Benefits of Effective money management for Your Youngsters' Future Monetary Prosperity - 2Sheinelle Jones will cohost fourth hour of 'Today' with Jenna Bush Hager: Here's what to know about her
- 3Journey Travel Objections for Your Next Experience
- 4Melodic Event: A Survey of \Energies and Exhibitions Assessed\ Live concert
- 5The most effective method to Amplify Profits from Gold Speculation: Systems and Tips
- A new mom skipped a routine appointment. An infected cut led to a devastating diagnosis
- Thousands of genomes reveal the wild wolf genes in most dogs’ DNA
- Pick Your Favored method of transportation
- Vote In favor of Your Favored Shades
- Comet C/2025 K1 (ATLAS) breaks apart in incredible telescope photos
- 2025 among world's three hottest years on record, WMO says
- Your big brain makes you human – count your neurons when you count your blessings
- Pick Your Favored kind of salad
- Telescope in Chile captures stunning new picture of a cosmic butterfly
